Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Imipenem anhydrous, cilastatin, and relebactam anhydrous

Drug class: Penem Antibacterial, Renal Dehydropeptidase Inhibitor, beta Lactamase Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Imipenem anhydrous, cilastatin, and relebactam anhydrous key facts

Drug class
Penem Antibacterial
Used for
RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible … (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (December 9, 2025); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Imipenem anhydrous, cilastatin, and relebactam anhydrous used for?
The FDA-approved label (Recarbrio, Merck Sharp & Dohme LLC, December 9, 2025) says: “RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Imipenem anhydrous, cilastatin, and relebactam anhydrous?
The “Adverse Reactions” section of the FDA label (Recarbrio, Merck Sharp & Dohme LLC, December 9, 2025) begins: “The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Imipenem anhydrous, cilastatin, and relebactam anhydrous?
The “Drug Interactions” section of the FDA label (Recarbrio, Merck Sharp & Dohme LLC, December 9, 2025) begins: “Ganciclovir: Avoid concomitant use. (7.1) Valproic Acid or Divalproex Sodium: Avoid concomitant use. (7.2) 7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir concomitantly with imipenem/cilastatin, a component of RECARBRIO.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Imipenem anhydrous, cilastatin, and relebactam anhydrous have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Imipenem anhydrous, cilastatin, and relebactam anhydrous?
The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated September 9, 2026). Ask your pharmacist about alternatives.
Has Imipenem anhydrous, cilastatin, and relebactam anhydrous been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Imipenem anhydrous, cilastatin, and relebactam anhydrous?
1 company lists prescription products of Imipenem anhydrous, cilastatin, and relebactam anhydrous in the FDA NDC Directory, including Merck Sharp & Dohme LLC.

What Imipenem anhydrous, cilastatin, and relebactam anhydrous is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). …

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, powder, for solution, intravenous), Recarbrio, Merck Sharp & Dohme LLC; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Imipenem anhydrous, cilastatin, and relebactam anhydrous side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.

Read more of this section

Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizures and Other Central Nervous System Adverse Reactions [see Warnings and Precautions (5.2)] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3)] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4)] Adult HABP/VABP Patients: The most frequently reported adverse reactions occurring in greater than or equal to 5% of patients treated with RECARBRIO were aspartate aminotransferase increased, anemia, alanine aminotransferase increased, diarrhea, hypokalemia, and hyponatremia. (6) Adult cUTI and cIAI Patients: The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients treated with imipenem/cilastatin plus relebactam 250 mg, the components of RECARBRIO, were diarrhea, nausea, headache, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, phlebitis/infusion site reactions, pyrexia, and hypertension. (6) Pediatric HABP/VABP, cUTI, and cIAI Patients: The most frequently reported adverse reactions occurring in greater than 3% of pediatric patients treated with RECARBRIO were vomiting, diarrhea, nausea, headache, phlebitis/infusion site reactions, and rash. To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients Overview of the Safety Evaluation of RECARBRIO in Adult Patients Safety was primarily evaluated in three active-controlled, double-blind trials in HABP/VABP, cUTI, and cIAI (Trials 1, 2, and 3, respectively). In the HABP/VABP trial (Trial 1), patients were treated with either RECARBRIO or piperacillin and tazobactam (4.5 grams). In the cUTI trial (Trial 2) and cIAI trial (Trial 3), patients in the treatment arms were treated with either imipenem 500 mg/cilastatin 500 mg and relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg (not an approved dose), and patients in the control arm were treated with imipenem 500 mg/cilastatin 500 mg plus placebo (IV normal saline). Across Trials 2 and 3, the mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days.

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. This is part of the section. Read the full label on DailyMed →

Imipenem anhydrous, cilastatin, and relebactam anhydrous drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Ganciclovir: Avoid concomitant use. (7.1) Valproic Acid or Divalproex Sodium: Avoid concomitant use. (7.2) 7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir concomitantly with imipenem/cilastatin, a component of RECARBRIO.

Read more of this section

Ganciclovir should not be used concomitantly with RECARBRIO unless the potential benefits outweigh the risks. 7.2 Valproic Acid Based on case reports in the literature concomitant use of carbapenems, including imipenem/cilastatin, components of RECARBRIO, with valproic acid or divalproex sodium may decrease valproic acid concentrations which may increase the risk of breakthrough seizures [see Warnings and Precautions (5.3)]. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. Avoid concomitant use of RECARBRIO with valproic acid or divalproex sodium. Consider alternative antibacterials other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. Read the full label on DailyMed →

Imipenem anhydrous, cilastatin, and relebactam anhydrous dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Adult Patients: The recommended dosage of RECARBRIO is 1.25 grams (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) administered by intravenous (IV) infusion over 30 minutes every 6 hours to adult patients with creatinine clearance (CLcr) 90 mL/min or greater.

Read more of this section

(2.1) Pediatric Patients weighing at least 2 kg: The recommended dosage of RECARBRIO for pediatric patients weighing at least 2kg varies by patient weight and age, with specific dosing recommendations as shown in the table below, (2.2): Recommended Dosage of RECARBRIO In Pediatric Patients Weighing at Least 2 kg Age Range Body Weight Dose Dosing Frequency Infusion Duration Birth Pediatric patients from birth (includes pediatric patients at least 37 weeks post-menstrual age) to less than 3 months 2 kg or greater RECARBRIO 37.5 Provides 15 mg/kg imipenem, 15 mg/kg cilastatin, and 7.5 mg/kg relebactam mg/kg Every 8 hours 60 minutes 3 months to less than 18 years less than 30 kg RECARBRIO 37.5 mg/kg Every 6 hours 60 minutes 3 months to less than 18 years 30 kg or greater RECARBRIO 1.25 Provides 500 mg imipenem, 500 mg cilastatin, and 250 mg, relebactam grams Every 6 hours 30 minutes Dose reduction is required in adult and pediatric (weighing at least 30 kg) patients with renal impairment. (2.3, 2.4) Do not administer RECARBRIO to adults with CLcr less than 15 mL/min unless hemodialysis is instituted within 48 hours after dose administration. (2.3) Do not administer RECARBRIO to pediatric patients weighing at least 30 kg with an eGFR less than 15 mL/min/1.73m 2 unless hemodialysis is instituted within 48 hours after dose administration. (2.4) See Full Prescribing Information for instructions for constituting supplied dry powder and subsequent required dilution. (2.5) See Full Prescribing Information for drug compatibilities and incompatibilities. (2.7, 2.8) 2.1 Recommended Dosage in Adult Patients The recommended dosage of RECARBRIO is 1.25 grams (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) administered by intravenous (IV) infusion over 30 minutes every 6 hours in adult patients with creatinine clearance (CLcr) of 90 mL/min or greater). The recommended duration of treatment with RECARBRIO is 4 days to 14 days. The duration of therapy should be guided by the severity and location of infection and clinical response. 2.2 Recommended Dosage in Pediatric Patients Weighing at Least 2 kg The recommended dosage of RECARBRIO in pediatric patients weighing at least 2 kg varies by patient weight and age, with specific dosing recommendations shown in Table 1. The recommended duration of treatment with RECARBRIO is 4 days to 14 days. The duration of therapy should be guided by the severity and location of infection and clinical response. RECARBRIO is not recommended in pediatric patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age) [see Indications and Usage (1.4) and Use in Specific Populations (8.4)].

Table from the label
Age RangeBody WeightDoseDosing FrequencyInfusion Duration
BirthPediatric patients from birth (includes pediatric patients at least 37 weeks post-menstrual age) to less than 3 months2 kg or greaterRECARBRIO 37.5Provides 15 mg/kg imipenem, 15 mg/kg cilastatin, and 7.5 mg/kg relebactam mg/kgEvery 8 hours60 minutes
3 months to less than 18 yearsless than 30 kgRECARBRIO 37.5 mg/kgEvery 6 hours60 minutes
3 months to less than 18 years30 kg or greaterRECARBRIO 1.25Provides 500 mg imipenem, 500 mg cilastatin, and 250 mg, relebactam gramsEvery 6 hours30 minutes

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. This is part of the section. Read the full label on DailyMed →

Imipenem anhydrous, cilastatin, and relebactam anhydrous in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Embryonic loss was observed in monkeys treated with imipenem/cilastatin, and fetal abnormalities were observed in relebactam-treated mice; therefore, advise pregnant women of the potential risks to pregnancy and the fetus. There are insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with RECARBRIO, imipenem, cilastatin, or relebactam in pregnant women.

Read more of this section

Developmental toxicity studies with imipenem and cilastatin (alone or in combination) administered parenterally during organogenesis to mice, rats, rabbits, and monkeys at doses 1 to 5 times the maximum recommended human dose (MRHD of imipenem 500 mg/cilastatin 500 mg every 6 hours for total daily doses of imipenem 2000 mg/cilastatin 2000 mg) based on body surface area comparison, showed no drug-induced fetal malformations. Embryofetal development studies with imipenem/cilastatin administered to cynomolgus monkeys at doses similar to the MRHD (based on body surface area comparison) showed an increase in embryonic loss. In an embryofetal study, parental administration of relebactam to pregnant mice during the period of organogenesis was associated with a non-dose responsive increase in the litter incidence of cleft palate at a plasma relebactam exposure approximately equal to the human exposure at the MRHD (250 mg every 6 hours for a daily dose of 1000 mg) and an increased percent litter incidence of total skeletal malformations at a plasma exposure approximately 6 times the human exposure at the MRHD. Reproductive studies with relebactam administered parenterally to pregnant rats and rabbits during the period of organogenesis at plasma exposures up to 7 and 24 times, respectively, the plasma exposure in humans at the MRHD showed no adverse effects on pregnancy or embryofetal development. Relebactam administered to rats during gestation through lactation was not associated with fetal toxicity, developmental delays, or impaired reproduction in first generation offspring at plasma exposures equivalent to 8 times the human exposure at the MRHD (see Data). The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects is 2 to 4% and miscarriage is 15 to 20% of clinically recognized pregnancies within the U.S. general population. Data Animal Data Imipenem and Cilastatin Reproductive toxicity studies with imipenem and cilastatin (alone or in combination) administered parenterally to mice, rats, and rabbits showed no evidence of effects on embryofetal (mice, rats, and rabbits) or pre/postnatal (rats) development. In embryofetal development studies, imipenem was administered intravenously to rats (gestation days (GD) 7 to 17), and rabbits (GD 6 to 18), at doses up to 900 and 60 mg/kg/day, respectively, approximately 4 and 0.6 times the MRHD (based on body surface area comparison).

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. This is part of the section. Read the full label on DailyMed →

When Imipenem anhydrous, cilastatin, and relebactam anhydrous should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity (severe systemic allergic reaction such as anaphylaxis) to any component of RECARBRIO. RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity to any component of RECARBRIO. (4)

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. Read the full label on DailyMed →

Imipenem anhydrous, cilastatin, and relebactam anhydrous overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

In the event of overdose, discontinue RECARBRIO, treat symptomatically, and institute general supportive treatment. Imipenem, cilastatin, and relebactam can be removed by hemodialysis [see Clinical Pharmacology (12.3)]. No clinical information is available on the use of hemodialysis to treat overdosage.

— FDA label: Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection, powder, for solution
RouteIntravenous
Prescription products1 in the FDA NDC Directory
Brand namesRecarbrio

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA212819
RECARBRIO
Msd Merck CoJuly 16, 2019 2, latest December 9, 2025
2025: Efficacy · 2020: Efficacy

Shortage status

To be discontinued · updated September 9, 2026 · first posted September 9, 2026

ProductRECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)
CompanyMerck Sharp & Dohme LLC

Ask your pharmacist whether your product is affected and what the options are.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2184142, 2184147
SPL set ID of the quoted labelbe32f468-738b-40df-a425-591e12f65159
FDA labels (SPL)1
FDA applicationsNDA212819
Active ingredients (FDA)CILASTATIN / IMIPENEM / RELEBACTAM

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Recarbrio, Merck Sharp & Dohme LLC, effective December 9, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers